Last reviewed · How we verify
Sarpogrelate SR 300mg
At a glance
| Generic name | Sarpogrelate SR 300mg |
|---|---|
| Also known as | Anplone SR |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease (PHASE4)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions (PHASE1)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions (PHASE1)
- A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions (PHASE1)
- A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions (PHASE1)
- SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study (PHASE4)
- Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sarpogrelate SR 300mg CI brief — competitive landscape report
- Sarpogrelate SR 300mg updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI